High expression levels of X-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de Novo acute myeloid leukemia

被引:142
作者
Tamm, I
Richter, S
Oltersdorf, D
Creutzig, U
Harbott, J
Scholz, F
Karawajew, L
Ludwig, WD
Wuchter, C
机构
[1] Univ Med Berlin, Robert Rossle Klin, HELIOS Klinikum Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
[2] Univ Munster, Childrens Hosp, Dept Pediat Hematol Oncol, D-4400 Munster, Germany
[3] Univ Giessen, Childrens Hosp, Oncogenet Lab, Giessen, Germany
[4] Humboldt Univ, Dept Hematol & Oncol, Berlin, Germany
关键词
D O I
10.1158/1078-0432.CCR-03-0642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Apoptosis-related proteins are important molecules for predicting chemotherapy response and prognosis in adult acute myeloid leukemia (AML). However, data on the expression and prognostic impact of these molecules in childhood AML are rare. Experimental Design: Using flow cytometry and Western blot analysis, we, therefore, investigated 45 leukemic cell samples from children with de novo AML enrolled and treated within the German AML-BFM93 study for the expression of apoptosis-regulating proteins [CD95, Bcl-2, Bax, Bcl-xL, procaspase-3, X-linked inhibitor of apoptosis protein (XIAP), cellular inhibitor of apoptosis protein-1 (cIAP-1), survivin]. Results: XIAP (P < 0.002) but no other apoptosis regulators showed maturation-dependent expression differences as determined by French-American-British (FAB) morphology with the highest expression levels observed within the immature M0/1 subtypes. XIAP (P < 0.01) and Bcl-xL (P < 0.01) expression was lower in patients with favorable rather than intermediate/poor cytogenetics. After a mean follow-up of 34 months, a shorter overall survival was associated with high expression levels of XIAP [30 (n = 10) versus 41 months (n = 34); P < 0.05] and survivin [27 (n = 10) versus 41 months (n = 34); P < 0.05]. Conclusions: We conclude that apoptosis-related molecules are associated with maturation stage, cytogenetic risk groups, and therapy outcome in childhood de novo AML. The observed association of XIAP with immature FAB types, intermediate/poor cytogenetics, and poor overall survival should be confirmed within prospective pediatric AML trials.
引用
收藏
页码:3737 / 3744
页数:8
相关论文
共 38 条
[1]   Expression and prognostic significance of survivin in de novo acute myeloid leukaemia [J].
Adida, C ;
Recher, C ;
Raffoux, E ;
Daniel, MT ;
Taksin, AL ;
Rousselot, P ;
Sigaux, F ;
Degos, L ;
Altieri, DC ;
Dombret, H .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :196-203
[2]   Anti-apoptosis gene, survivin, and prognosis of neuroblastoma [J].
Adida, C ;
Berrebi, D ;
Peuchmaur, M ;
Reyes-Mugica, M ;
Altieri, DC .
LANCET, 1998, 351 (9106) :882-883
[3]  
Adida C, 2000, BLOOD, V96, P1921
[4]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[5]  
BENE MC, 1995, LEUKEMIA, V9, P1783
[6]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[7]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[8]   Cytokine-regulated expression of survivin in myeloid leukemia [J].
Carter, BZ ;
Milella, M ;
Altieri, DC ;
Andreeff, M .
BLOOD, 2001, 97 (09) :2784-2790
[9]   Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia [J].
Carter, BZ ;
Milella, M ;
Tsao, T ;
McQueen, T ;
Schober, WD ;
Hu, W ;
Dean, NM ;
Steelman, L ;
McCubrey, JA ;
Andreeff, M .
LEUKEMIA, 2003, 17 (11) :2081-2089
[10]   Idarubicin improves blast cell clearance during induction therapy in children with AML:: results of study AML-BFM 93 [J].
Creutzig, U ;
Ritter, J ;
Zimmermann, M ;
Hermann, J ;
Gadner, H ;
Sawatzki, DB ;
Niemeyer, CM ;
Schwabe, D ;
Selle, B ;
Boos, J ;
Kühl, J ;
Feldges, A .
LEUKEMIA, 2001, 15 (03) :348-354